Syncona, the majority shareholder of Freeline Therapeutics, has made a bid to acquire the biotech less than a month after it revealed data from two Gaucher disease patients in an early-phase gene therapy study. The total value of the proposed acquisition is $24.4 million, Syncona told Endpoints News in an email.

The investment trust co-founded Freeline alongside University College London in 2015, with Syncona currently owning 57.9% of company shares, according to an SEC filing. But the trust has now placed an offer to buy the rest for $5 apiece, according to another SEC filing.

The bid represents a 20% premium on Freeline’s weighted average share price of $4.16 since the data release on Oct. 4 through Oct. 16. Syncona said it plans to further discuss the offer with the UK biotech. Freeline’s stock $FRLN surged by as much as 12% to $5 on Wednesday in response to the news.

Freeline’s Gaucher therapy, dubbed FLT201, is under investigation in the Phase I/II GALILEO-1 trial. FLT201 uses an AAVS3 capsid to deliver a transgene to the liver to produce an engineered version of the glucocerebrosidase (GCase) enzyme, which is missing in Gaucher disease patients.

Results from two patients in GALILEO-1 shared earlier this month hinted at favorable tolerability, with no cases of liver transaminase elevations or infusion reactions observed at the data cutoff. One patient was 13 weeks post-treatment administration, while the second patient was six weeks in.

Both patients also saw an increase in plasma GCase levels. The first patient had an almost 700-fold increase from baseline to more than 70 μmol/L/h GCase at 12 weeks. The second patient had more than a 300-fold increase from baseline to around 30 μmol/L/h at four weeks.

These recent developments mark a welcome change for Freeline, which was forced to hit the brakes on its early-stage gene therapy program for hemophilia B in 2021 due to CMC concerns raised by the FDA.

In July last year, the company published long-term data from a Phase I/II dose-finding trial of the bleeding disorder treatment named FLT180a. But, as part of a broader strategic reprioritization, Freeline stopped investing in the FLT180a program in November 2022, per an earnings report.

Source:
https://endpts.com/syncona-eyes-buyout-of-gene-therapy-biotech-freeline-after-early-data-in-two-gaucher-patients/
About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Scientists develop potential stealth cancer therapy

Credit: ACS Central Science (2024). DOI: 10.1021/acscentsci.4c00559Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at...

read more

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
READ MORE

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
READ MORE
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.
READ MORE